Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Inflammation
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1492538
This article is part of the Research Topic Advancements in Sepsis Diagnosis Utilizing Next-Generation Sequencing Approaches for Personalized Medicine View all articles

Upregulation of CRISP3 and its clinical values in adult sepsis: a comprehensive analysis based on microarrays and two retrospective cohort study

Provisionally accepted
An-qiang Zhang An-qiang Zhang 1Da-Lin Wen Da-Lin Wen 1*Xin-Xin Ma Xin-Xin Ma 2*Fei Zhang Fei Zhang 3*Guo-Sheng Chen Guo-Sheng Chen 1*Kelimu Maimaiti Kelimu Maimaiti 3*Gang Xu Gang Xu 3*Jian-Xin Jiang Jian-Xin Jiang 3*Hong-Xiang Lu Hong-Xiang Lu 1,3*
  • 1 State Key Laboratory of Trauma, Burn and Combined Injury, Third Military Medical University, Chongqing, China, Chongqing, China
  • 2 Xinjiang Medical University, Ürümqi, Xinjiang Uyghur Region, China
  • 3 Department of traumatic Orthopaedics, General Hospital of Xinjiang Military Region, Urumuqi, China, Urumuqi, China

The final, formatted version of the article will be published soon.

    Background Current evidences indicate cysteine-rich secretory protein 3 (CRISP-3) is an immunoregulatory factor. Nevertheless, no study explored the relationships between the values of CRISP3 and sepsis. Methods We conducted a comprehensive literature search and meta-analysis from Gene Expression Omnibus (GEO) and Array Express to determine the expression of CRISP3 in sepsis patients. Then, we explored whether the plasma CRISP3 could serve as a potential biomarker to predict the risk of sepsis via two retrospective trauma cohorts. The prediction power was evaluated with area under the curve (AUC). Results Totally, 23 datasets were recruited for the comprehensive meta-analysis, and the combined standardized mean difference (SMD) of CRISP3 was 0.90(0.50-1.30) (p<0.001), suggesting CRISP3 was overexpressed in the sepsis patients. Meanwhile, sepsis patients had higher CRISP3 concentrations than non-sepsis patients in 54 trauma patients (p<0.001). Plasma CRISP3 on admission were significantly associated with the incidence of sepsis (OR=1.004(1.002-1.006), p<0.001). As a predictive biomarker, CRISP3 obtained a better AUC (0.811 (0.681-0.905)) than C-reaction protein (CRP) (0.605 (0.463-0.735)), procalcitonin (PCT) (0.554(0.412-0.689)) and SOFA (0.754(0.618-0.861)). Additionally, the clinical relationships between plasma CRISP3 and sepsis were verified in another trauma cohort with 166 patients (OR=1.002(1.001-1.003), p<0.001). The AUC of CRISP3 was 0.772 (0.701-0.834), which was better than that of CRP (0.521(0.442-0.599)) and PCT (0.531(0.452-0.609)), except for SOFA (0.791(0.717-0.853)). Conclusion Our study indicated and validated CRISP3 was highly expressed in sepsis. More importantly, CRISP3 might serve as a latent biomarker to predict the risk of sepsis.

    Keywords: CRISP3, Sepsis, prediction, Meta-analysis, biomarker

    Received: 07 Sep 2024; Accepted: 31 Oct 2024.

    Copyright: © 2024 Zhang, Wen, Ma, Zhang, Chen, Maimaiti, Xu, Jiang and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Da-Lin Wen, State Key Laboratory of Trauma, Burn and Combined Injury, Third Military Medical University, Chongqing, China, Chongqing, China
    Xin-Xin Ma, Xinjiang Medical University, Ürümqi, Xinjiang Uyghur Region, China
    Fei Zhang, Department of traumatic Orthopaedics, General Hospital of Xinjiang Military Region, Urumuqi, China, Urumuqi, China
    Guo-Sheng Chen, State Key Laboratory of Trauma, Burn and Combined Injury, Third Military Medical University, Chongqing, China, Chongqing, China
    Kelimu Maimaiti, Department of traumatic Orthopaedics, General Hospital of Xinjiang Military Region, Urumuqi, China, Urumuqi, China
    Gang Xu, Department of traumatic Orthopaedics, General Hospital of Xinjiang Military Region, Urumuqi, China, Urumuqi, China
    Jian-Xin Jiang, Department of traumatic Orthopaedics, General Hospital of Xinjiang Military Region, Urumuqi, China, Urumuqi, China
    Hong-Xiang Lu, State Key Laboratory of Trauma, Burn and Combined Injury, Third Military Medical University, Chongqing, China, Chongqing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.